![[Rinsho ketsueki] The Japanese journal of clinical hematology](https://originalfileserver.aminer.cn/sys/aminer/magazine.png)
A 76-year-old woman with stage IIIB squamous cell lung carcinoma developed pancytopenia following maintenance therapy with durvalumab. She was diagnosed with squamous cell lung carcinoma (T4N2M0, stageIIIB) in December 2023. Following a favorable response to chemoradiotherapy, maintenance therapy with durvalumab was initiated in June 2024. Thrombocytopenia was observed starting in August, and platelet count had decreased to 22,000/µl in October, leading to the discontinuation of durvalumab. However, the condition progressed to pancytopenia. Bone marrow biopsy revealed hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis. Additional findings included paroxysmal nocturnal hemoglobinuria-type blood cells and fatty marrow replacement on spinal MRI. Based on these comprehensive findings, the patient was diagnosed with aplastic anemia (AA) in January 2025. Immunosuppressive therapy combining antithymocyte globulin, cyclosporine A, and eltrombopag was initiated in February 2025, resulting in a favorable response. AA is a relatively rare immune-related adverse event, and reports of AA induced by durvalumab are extremely limited. This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy.
Central nervous system (CNS) viral infections after allogeneic hematopoietic stem cell transplantation are associated with poor prognosis and have limited therapeutic options. We report three cases of refractory CNS viral infection treated by combination therapy with antiviral agents and intrathecal immunoglobulin administration. Case 1 involved cytomegalovirus encephalitis, Case 2 varicella zoster virus meningitis, and Case 3 human herpesvirus 6 encephalitis; all were resistant to antiviral agents. Two patients achieved viral DNA negativity in cerebrospinal fluid, and none experienced adverse events related to intrathecal injection. Although no intrathecal immunoglobulin products have been approved for use in Japan, our findings suggest that this treatment may be a viable option in selected refractory cases. Further studies are warranted to clarify the optimal agent, dosage, and schedule.
The complement system, which plays a key role in innate immunity, facilitates the elimination of foreign and endogenous substances in the body. Consequently, while a balance between complement activation and regulation is typically maintained, a disruption of this balance can lead to various diseases. Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) are diseases in which abnormal complement regulatory factors cause excessive complement activation. To accurately diagnose diseases such as aHUS, international standard complement tests including activation markers such as Ba and sC5b-9 are used. The Japanese Society for Complement Research has contributed to the standardization of the International Complement Society and has established this testing system in Japan. In the present study, we revealed that the Ba level serves as a good predictive marker for the onset of thrombotic microangiopathy, a complication that typically occurs following hematopoietic stem cell transplantation. We also showed that complement activation levels rise more frequently postpartum than during pregnancy. Considering the growing number of drugs targeting the complement pathway, it is speculated that these complement markers will become available for testing in clinical settings in Japan.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Advances in supportive care, infection control, and graft-versus-host disease management have substantially reduced non-relapse mortality, leading to improved transplant outcomes. However, post-transplant relapse remains the leading cause of treatment failure, particularly in patients with adverse genetic abnormalities or active disease at transplantation. Post-transplant maintenance therapy has emerged as a strategy to prevent relapse by providing a "third anti-leukemic effect" that complements the cytotoxic effect of conditioning regimens and the graft-versus-leukemia immune response. Maintenance approaches can be broadly categorized into prophylactic therapy administered during molecular remission and preemptive therapy initiated upon detection of measurable residual disease (MRD). This review summarizes the current concepts of post-transplant maintenance therapy in AML/MDS, with a particular focus on hypomethylating agents such as azacitidine and FLT3 inhibitors. It also discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.
BACKGROUND:Myelodysplastic syndromes (MDS) are classified into de novo and secondary forms. MDS among atomic bomb survivors (A-bomb-related MDS) is considered radiation-associated secondary MDS, whereas therapy-related MDS (t-MDS) develops after cytotoxic therapy and generally has a poor prognosis. However, differences between these two secondary MDS entities remain unclear. METHODS:We analyzed patients registered in the Nagasaki MDS cohort who were diagnosed between January 1985 and December 2023. Sixty A-bomb-related MDS and 150 t-MDS cases were included. Clinical characteristics, IPSS-R risk categories, overall survival (OS), and cytogenetic abnormalities at diagnosis were compared. RESULTS:The distribution of IPSS-R risk and cytogenetic risk categories did not differ significantly between groups. Nevertheless, median OS was significantly longer in A-bomb-related MDS than in t-MDS (65 vs. 19 months). Cytogenetic profiling revealed different features between groups, including a significantly higher frequency of monosomy 7 in t-MDS and of balanced structural abnormalities in A-bomb-related MDS. Balanced structural abnormalities were not clearly associated with prognosis. CONCLUSIONS:Although both A-bomb-related MDS and t-MDS are both classified as secondary MDS, they showed distinct prognostic and cytogenetic features. These findings suggest that the two conditions represent clinically distinct entities with different pathophysiology.